Oregon Public Employees Retirement Fund Increases Stake in Charles River Laboratories Intl. Inc (CRL)

Oregon Public Employees Retirement Fund increased its position in shares of Charles River Laboratories Intl. Inc (NYSE:CRL) by 2.6% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 18,893 shares of the medical research company’s stock after buying an additional 484 shares during the period. Oregon Public Employees Retirement Fund’s holdings in Charles River Laboratories Intl. were worth $2,542,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in the company. BlackRock Inc. increased its stake in shares of Charles River Laboratories Intl. by 7.0% during the second quarter. BlackRock Inc. now owns 4,446,965 shares of the medical research company’s stock valued at $499,216,000 after buying an additional 292,685 shares during the period. Renaissance Technologies LLC increased its stake in shares of Charles River Laboratories Intl. by 3.8% during the second quarter. Renaissance Technologies LLC now owns 1,515,300 shares of the medical research company’s stock valued at $170,108,000 after buying an additional 55,000 shares during the period. Wells Fargo & Company MN increased its stake in shares of Charles River Laboratories Intl. by 5.4% during the second quarter. Wells Fargo & Company MN now owns 1,316,635 shares of the medical research company’s stock valued at $147,806,000 after buying an additional 67,439 shares during the period. First Trust Advisors LP increased its stake in shares of Charles River Laboratories Intl. by 56.7% during the third quarter. First Trust Advisors LP now owns 858,962 shares of the medical research company’s stock valued at $115,565,000 after buying an additional 310,975 shares during the period. Finally, Brown Advisory Inc. increased its stake in shares of Charles River Laboratories Intl. by 5.4% during the second quarter. Brown Advisory Inc. now owns 702,500 shares of the medical research company’s stock valued at $78,863,000 after buying an additional 36,219 shares during the period. Hedge funds and other institutional investors own 96.02% of the company’s stock.

In other news, insider David Ross Smith sold 1,249 shares of the business’s stock in a transaction dated Monday, August 13th. The stock was sold at an average price of $120.05, for a total transaction of $149,942.45. Following the sale, the insider now owns 13,690 shares in the company, valued at $1,643,484.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Deborah Turner Kochevar sold 4,066 shares of the business’s stock in a transaction dated Tuesday, September 4th. The stock was sold at an average price of $123.66, for a total value of $502,801.56. Following the sale, the director now owns 10,190 shares in the company, valued at approximately $1,260,095.40. The disclosure for this sale can be found here. 2.10% of the stock is owned by insiders.

Several equities analysts have recently commented on CRL shares. Bank of America raised their price target on Charles River Laboratories Intl. from $120.00 to $125.00 and gave the company a “buy” rating in a research note on Monday, July 16th. Royal Bank of Canada upgraded Charles River Laboratories Intl. from a “sector perform” rating to an “outperform” rating and set a $131.00 price target on the stock in a research note on Tuesday, July 17th. ValuEngine upgraded Charles River Laboratories Intl. from a “hold” rating to a “buy” rating in a research note on Wednesday, July 18th. Jefferies Financial Group restated a “buy” rating and set a $140.00 price target on shares of Charles River Laboratories Intl. in a research note on Friday, July 20th. Finally, SunTrust Banks raised their price target on Charles River Laboratories Intl. to $135.00 and gave the company a “buy” rating in a research note on Thursday, August 9th. Eight investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. Charles River Laboratories Intl. has an average rating of “Buy” and a consensus price target of $128.50.

CRL opened at $123.50 on Friday. Charles River Laboratories Intl. Inc has a 1 year low of $96.70 and a 1 year high of $135.90. The company has a debt-to-equity ratio of 1.52, a quick ratio of 1.48 and a current ratio of 1.72. The stock has a market capitalization of $5.85 billion, a price-to-earnings ratio of 21.37, a P/E/G ratio of 1.53 and a beta of 0.74.

Charles River Laboratories Intl. (NYSE:CRL) last posted its earnings results on Wednesday, August 8th. The medical research company reported $1.62 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.46 by $0.16. Charles River Laboratories Intl. had a return on equity of 25.26% and a net margin of 6.38%. The company had revenue of $585.30 million for the quarter, compared to analyst estimates of $570.65 million. During the same quarter in the previous year, the firm earned $1.29 earnings per share. The firm’s quarterly revenue was up 24.8% compared to the same quarter last year. Sell-side analysts predict that Charles River Laboratories Intl. Inc will post 5.91 EPS for the current fiscal year.

Charles River Laboratories Intl. Profile

Charles River Laboratories International, Inc, an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services worldwide. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).

Featured Story: What is a conference call?

Want to see what other hedge funds are holding CRL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Charles River Laboratories Intl. Inc (NYSE:CRL).

Institutional Ownership by Quarter for Charles River Laboratories Intl. (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories Intl. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply